This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

NPS Pharma: Bullish Options Trade Into the Gattex FDA Panel

BEDMINSTER, NJ (TheStreet) -- NPS Pharmaceuticals (NPSP) is slated to face an FDA advisory panel committee for Gattex for the treatment of adults with short bowl syndrome on Oct. 16. The company's FDA drug approval decision date is Dec. 30. I've structured an options trade to play the NPS Pharma Gattex panel below, but first, a brief explanation of the FDA advisory panel process.

The FDA often convenes advisory panels as part of the drug review process. These panels, comprised of outside experts, provide advice to the FDA on whether or not to approve a drug. Over the course of a day (or half day in some cases), the FDA and the drug sponsor present efficacy and safety data to the panel's experts, who ask questions and deliberate before voting on whether or not to recommend a drug's approval. It should be noted that advisory panels are just that -- advisory -- and that FDA makes the final decision on drug approvals. Still, these panels are among the most exciting biotech catalysts for traders.

Trading FDA drug advisory panels can be tricky because there are several, potentially major, interim catalysts leading up to the day of the meeting. [Stocks are almost always halted on the day of advisory panels.]

The first catalyst is the release of FDA's briefing documents that typically occurs two days prior to the meeting. The briefing documents usually include the FDA's clinical review of the drug. An FDA review that is surprisingly negative or positive often causes a lot of stock volatility.

If you want to trade around these FDA panels, you'll first want to decide whether to place a trade before the release of the FDA briefing documents or post release (but before the actual meeting takes place.) An alternative trading strategy is to simply wait until the meeting is over and fade the move once the stock is unhalted.

Let's talk about the NPS Pharma trade into its Oct. 16 Gattex advisory panel. In this trade I will be using a no-cost bullish strategy and I will execute the trade prior to the release of the briefing documents. NPS Pharma has run up strongly into the panel already, with the stock moving from around $7 to $10 per share. Options currently imply an up or down move in the stock of $2.50 per share from current levels and analysts currently favors a positive outcome and a share pop to the $12-to-$13 per share range. Here is the trade:

Buy 10 OCT 9.0 strike Calls at 1.80 = $1,800
Sell (10) OCT 10.0 strike Calls at 1.15 = $(1,150)
Sell (10) OCT 11.0 strike Calls at 0.70 = $(700)
Buy 10 OCT 12.0 strike Calls at 0.35 = $350
Sell (10) OCT 7.0 strike Puts at 0.30 = $(300)
Initial P&L = $0

P&L Diagram:

This is a long Call Condor fully financed by a sold Put. The trade costs nothing, excluding commissions. The trade profits as long as the stock settles between $9 and $12 by expiration --note this is below current analysts estimates that tend to be overly aggressive. Maximum profit is achieved between $10 and $11 a share and results in a $1,000 gain for this position size.

Losses start at $7 and accelerate below this level given the trade structure uses a short Put (where one is basically short 1,000 shares for this size.) The Call Condor should be executed as one order with a broker. There is some optionality with the sold Put portion of the trade: It can be sold pre-briefing documents or after release but (obviously) before the stock gets halted. If you are able to catch a sell-off or a ramp up of implied volatility it may be possible to get a higher sale value and actually trade into the strategy at a credit. (Of course, if the stock moves higher, selling the Puts may no longer make sense).

Pelz has no position in NPS Pharma.

To learn more about using options to trade biotech stocks, check out Tony Pelz's book, The Biotech Trader Handbook or subscribe to Chimera Research Group.

Tony Pelz was a trader on a major European bank's proprietary trading desk, responsible for a portfolio with limits of more than $200 million. Prior to proprietary trading, Pelz worked with several global investment banks in roles ranging from corporate finance, M&A to credit and business development. He is author of The Biotech Trader Handbook, 2nd Edition, co-founder of the small-cap biotech research and trading site Chimera Research Group and operator of PelzOptions.com. Pelz currently resides in Denver, Colorado where he trades for his own account.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,563.30 -317.06 -1.88%
S&P 500 1,930.67 -39.40 -2.00%
NASDAQ 4,369.7730 -93.1290 -2.09%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs